Share ownership Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/01/2026 GMT			5-day change	1st Jan Change
69.59 ^USD	+2.94%		+5.04%	+4.82%

01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI

Share class: Arrowhead Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	126,098,111	118,882,205 ( 94.28 %)	0	94.28 %

Major shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.19 %	19,271,815	14.19 %	1 279 M $
Vanguard Fiduciary Trust Co. 11.81 %	16,035,870	11.81 %	1 065 M $
Avoro Capital Advisor LLC 8.026 %	10,900,000	8.026 %	724 M $
STATE STREET CORPORATION 4.711 %	6,397,364	4.711 %	425 M $
Fidelity Management & Research Co. LLC 4.241 %	5,759,830	4.241 %	382 M $
Slate Path Capital LP 3.668 %	4,982,000	3.668 %	331 M $
Christopher Anzalone 2.793 %	3,792,739	2.793 %	252 M $
Geode Capital Management LLC 2.305 %	3,131,042	2.305 %	208 M $
The Invus Group LLC 1.966 %	2,669,880	1.966 %	177 M $
The Invus Group LLC 1.966 %	2,669,880	1.966 %	177 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	77.47%
State Street Corp.	4.71%
Individuals	4.48%
Other	3.76%
Silvercrest Asset Management Group, Inc.	0.2%
Schweizerische Nationalbank	0.16%
Manulife Financial Corp.	0.05%
Governments	0.05%
SEI Investments Co.	0.04%
Unknown	9.08%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	76.94%
United Kingdom	4.98%
Individuals	4.48%
Norway	1.44%
Canada	0.67%
Luxembourg	0.51%
Netherlands	0.35%
Switzerland	0.35%
Sweden	0.25%
Denmark	0.24%
Germany	0.19%
China	0.16%
Ireland	0.08%
Australia	0.08%
Austria	0.05%
Japan	0.05%
France	0.05%
Taiwan	0.02%
Israel	0.01%
Hong Kong	0.01%
Czech Republic	0.01%

Based on 1000 largest holdings

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

Calendar

02-04 - Q1 2026 Earnings Release

More about the company